| Stage | CTC | CEA | NSE | CYFRA21-1 | SCCA |
|---|---|---|---|---|---|
| ALL | 81% | 34% | 25% | 50% | 30% |
| Stage I | 67% | 11% | 6% | 29% | 9% |
| Stage II | 71% | 30% | 6% | 55% | 25% |
| Stage III、IV | 86% | 37% | 30% | 52% | 30% |
肺癌輔助診斷
I 期肺癌檢測敏感度 67%
肺癌總體檢測敏感度80%
肺癌總體檢測特異度88%
治療療效評估
評估腫瘤活性狀態，彌補RECIST標準的不足，治療方案選擇更精準
術后監測復發
動態隨訪，輔助胸部CT，及時預警復發